Novo Holdings Co-Leads EUR 6M Seed Financing in Asgard Therapeutics
- Asgard Therapeutics developing in vivo immune cell reprogramming technology to reinstate cancer immunogenicity
- Funds will be used to further develop off-the-shelf and personalized therapy programs for multiple oncology indications
- Novo Holdings co-led the financing with Boehringer Ingelheim Venture Fund and Industrifonden
Copenhagen, Denmark – Novo Holdings, a leading international life science investor, today announces that it has co-led the EUR 6 million seed financing in Asgard Therapeutics AB (“Asgard”), a private biotech company pioneering in vivo direct cell reprogramming approaches to elicit potent anti-cancer immune responses.